{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T14:00:00Z","timestamp":1775656800951,"version":"3.50.1"},"reference-count":84,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,1,15]],"date-time":"2024-01-15T00:00:00Z","timestamp":1705276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,15]],"date-time":"2024-01-15T00:00:00Z","timestamp":1705276800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000288","name":"Royal Society","doi-asserted-by":"publisher","award":["URF\\R1\\201461"],"award-info":[{"award-number":["URF\\R1\\201461"]}],"id":[{"id":"10.13039\/501100000288","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000266","name":"RCUK | Engineering and Physical Sciences Research Council","doi-asserted-by":"publisher","award":["EP\/X024733\/1"],"award-info":[{"award-number":["EP\/X024733\/1"]}],"id":[{"id":"10.13039\/501100000266","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000266","name":"RCUK | Engineering and Physical Sciences Research Council","doi-asserted-by":"publisher","award":["EP\/X024733\/1"],"award-info":[{"award-number":["EP\/X024733\/1"]}],"id":[{"id":"10.13039\/501100000266","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004815","name":"Isaac Newton Trust","doi-asserted-by":"publisher","award":["RG89305"],"award-info":[{"award-number":["RG89305"]}],"id":[{"id":"10.13039\/501100004815","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Mach Intell"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Monoclonal antibodies have emerged as key therapeutics. In particular, nanobodies, small, single-domain antibodies that are naturally expressed in camelids, are rapidly gaining momentum following the approval of the first nanobody drug in 2019. Nonetheless, the development of these biologics as therapeutics remains a challenge. Despite the availability of established in vitro directed-evolution technologies that are relatively fast and cheap to deploy, the gold standard for generating therapeutic antibodies remains discovery from animal immunization or patients. Immune-system-derived antibodies tend to have favourable properties in vivo, including long half-life, low reactivity with self-antigens and low toxicity. Here we present AbNatiV, a deep learning tool for assessing the nativeness of antibodies and nanobodies, that is, their likelihood of belonging to the distribution of immune-system-derived human antibodies or camelid nanobodies. AbNatiV is a multipurpose tool that accurately predicts the nativeness of Fv sequences from any source, including synthetic libraries and computational design. It provides an interpretable score that predicts the likelihood of immunogenicity, and a residue-level profile that can guide the engineering of antibodies and nanobodies indistinguishable from immune-system-derived ones. We further introduce an automated humanization pipeline, which we applied to two nanobodies. Laboratory experiments show that AbNatiV-humanized nanobodies retain binding and stability at par or better than their wild type, unlike nanobodies that are humanized using conventional structural and residue-frequency analysis. We make AbNatiV available as downloadable software and as a webserver.<\/jats:p>","DOI":"10.1038\/s42256-023-00778-3","type":"journal-article","created":{"date-parts":[[2024,1,15]],"date-time":"2024-01-15T11:02:25Z","timestamp":1705316545000},"page":"74-91","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":67,"title":["Assessing antibody and nanobody nativeness for hit selection and humanization with AbNatiV"],"prefix":"10.1038","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-5502-5961","authenticated-orcid":false,"given":"Aubin","family":"Ramon","sequence":"first","affiliation":[]},{"given":"Montader","family":"Ali","sequence":"additional","affiliation":[]},{"given":"Misha","family":"Atkinson","sequence":"additional","affiliation":[]},{"given":"Alessio","family":"Saturnino","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6839-3320","authenticated-orcid":false,"given":"Kieran","family":"Didi","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2705-1417","authenticated-orcid":false,"given":"Cristina","family":"Visentin","sequence":"additional","affiliation":[]},{"given":"Stefano","family":"Ricagno","sequence":"additional","affiliation":[]},{"given":"Xing","family":"Xu","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9366-9923","authenticated-orcid":false,"given":"Matthew","family":"Greenig","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6228-2221","authenticated-orcid":false,"given":"Pietro","family":"Sormanni","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2024,1,15]]},"reference":[{"key":"778_CR1","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/S0968-0004(00)01725-4","volume":"25","author":"RD Goldman","year":"2000","unstructured":"Goldman, R. D. Antibodies: indispensable tools for biomedical research. Trends Biochem. Sci. 25, 593\u2013595 (2000).","journal-title":"Trends Biochem. Sci."},{"key":"778_CR2","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3390\/antib9020015","volume":"9","author":"NH Trier","year":"2020","unstructured":"Trier, N. H. & Houen, G. Antibodies as diagnostic targets and as reagents for diagnostics. Antibodies 9, 15 (2020).","journal-title":"Antibodies"},{"key":"778_CR3","doi-asserted-by":"publisher","first-page":"2153410","DOI":"10.1080\/19420862.2022.2153410","volume":"15","author":"H Kaplon","year":"2023","unstructured":"Kaplon, H., Crescioli, S., Chenoweth, A., Visweswaraiah, J. & Reichert, J. M. Antibodies to watch in 2023. mAbs 15, 2153410 (2023).","journal-title":"mAbs"},{"key":"778_CR4","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1038\/363446a0","volume":"363","author":"C Hamers-Casterman","year":"1993","unstructured":"Hamers-Casterman, C. et al. Naturally occurring antibodies devoid of light chains. Nature 363, 446\u2013448 (1993).","journal-title":"Nature"},{"key":"778_CR5","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1146\/annurev-biochem-063011-092449","volume":"82","author":"S Muyldermans","year":"2013","unstructured":"Muyldermans, S. Nanobodies: natural single-domain antibodies. Annu. Rev. Biochem. 82, 775\u2013797 (2013).","journal-title":"Annu. Rev. Biochem."},{"key":"778_CR6","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1056\/NEJMoa1505533","volume":"374","author":"F Peyvandi","year":"2016","unstructured":"Peyvandi, F. et al. Caplacizumab for acquired thrombotic thrombocytopenic purpura. New Engl. J. Med. 374, 511\u2013522 (2016).","journal-title":"New Engl. J. Med."},{"key":"778_CR7","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/256495a0","volume":"256","author":"G K\u00f6hler","year":"1975","unstructured":"K\u00f6hler, G. & Milstein, C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256, 495\u2013497 (1975).","journal-title":"Nature"},{"key":"778_CR8","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1038\/348552a0","volume":"348","author":"J McCafferty","year":"1990","unstructured":"McCafferty, J., Griffiths, A. D., Winter, G. & Chiswell, D. J. Phage antibodies: filamentous phage displaying antibody variable domains. Nature 348, 552\u2013554 (1990).","journal-title":"Nature"},{"key":"778_CR9","doi-asserted-by":"publisher","first-page":"9137","DOI":"10.1039\/C8CS00523K","volume":"47","author":"P Sormanni","year":"2018","unstructured":"Sormanni, P., Aprile, F. A. & Vendruscolo, M. Third generation antibody discovery methods: in silico rational design. Chem. Soc. Rev. 47, 9137\u20139157 (2018).","journal-title":"Chem. Soc. Rev."},{"key":"778_CR10","doi-asserted-by":"publisher","DOI":"10.1039\/d2cb00231k","author":"L Sell\u00e9s Vidal","year":"2023","unstructured":"Sell\u00e9s Vidal, L., Isalan, M., Heap, J. T. & Ledesma-Amaro, R. A primer to directed evolution: current methodologies and future directions. RSC Chem. Biol. https:\/\/doi.org\/10.1039\/d2cb00231k (2023).","journal-title":"RSC Chem. Biol."},{"key":"778_CR11","doi-asserted-by":"publisher","first-page":"5153","DOI":"10.1073\/pnas.1324022111","volume":"111","author":"AJ Murphy","year":"2014","unstructured":"Murphy, A. J. et al. Mice with megabase humanization of their immunoglobulin genes generate antibodies as efficiently as normal mice. Proc. Natl Acad. Sci. USA 111, 5153\u20135158 (2014).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"778_CR12","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1038\/nbt.2825","volume":"32","author":"E-C Lee","year":"2014","unstructured":"Lee, E.-C. et al. Complete humanization of the mouse immunoglobulin loci enables efficient therapeutic antibody discovery. Nat. Biotechnol. 32, 356\u2013363 (2014).","journal-title":"Nat. Biotechnol."},{"key":"778_CR13","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1038\/nm1080","volume":"10","author":"E Traggiai","year":"2004","unstructured":"Traggiai, E. et al. An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus. Nat. Med. 10, 871\u2013875 (2004).","journal-title":"Nat. Med."},{"key":"778_CR14","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1038\/nature06890","volume":"453","author":"J Wrammert","year":"2008","unstructured":"Wrammert, J. et al. Rapid cloning of high-affinity human monoclonal antibodies against influenza virus. Nature 453, 667\u2013671 (2008).","journal-title":"Nature"},{"key":"778_CR15","doi-asserted-by":"crossref","unstructured":"Lonberg, N. Fully human antibodies from transgenic mouse and phage display platforms. Current Opin. Immunol. 20, 450\u2013459 (2008).","DOI":"10.1016\/j.coi.2008.06.004"},{"key":"778_CR16","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1073\/pnas.1616408114","volume":"114","author":"T Jain","year":"2017","unstructured":"Jain, T. et al. Biophysical properties of the clinical-stage antibody landscape. Proc. Natl Acad. Sci. USA 114, 944\u2013949 (2017).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"778_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12929-019-0592-z","volume":"27","author":"R-M Lu","year":"2020","unstructured":"Lu, R.-M. et al. Development of therapeutic antibodies for the treatment of diseases. J. Biomed. Sci. 27, 1 (2020).","journal-title":"J. Biomed. Sci."},{"key":"778_CR18","doi-asserted-by":"publisher","first-page":"e1700488","DOI":"10.1126\/sciadv.1700488","volume":"3","author":"FA Aprile","year":"2017","unstructured":"Aprile, F. A. et al. Selective targeting of primary and secondary nucleation pathways in A\u03b242 aggregation using a rational antibody scanning method. Sci. Adv. 3, e1700488 (2017).","journal-title":"Sci. Adv."},{"key":"778_CR19","doi-asserted-by":"publisher","first-page":"9902","DOI":"10.1073\/pnas.1422401112","volume":"112","author":"P Sormanni","year":"2015","unstructured":"Sormanni, P., Aprile, F. A., Vendruscolo, M. & Tessier, P. M. Rational design of antibodies targeting specific epitopes within intrinsically disordered proteins. Proc. Natl Acad. Sci. USA 112, 9902\u20139907 (2015).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"778_CR20","doi-asserted-by":"publisher","unstructured":"Aguilar Rangel, M. et al. Fragment-based computational design of antibodies targeting structured epitopes. Sci. Adv. https:\/\/doi.org\/10.1126\/sciadv.abp9 (2022).","DOI":"10.1126\/sciadv.abp9"},{"key":"778_CR21","doi-asserted-by":"publisher","first-page":"10900","DOI":"10.1073\/pnas.1707171114","volume":"114","author":"D Baran","year":"2017","unstructured":"Baran, D. et al. Principles for computational design of binding antibodies. Proc. Natl Acad. Sci. USA 114, 10900\u201310905 (2017).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"778_CR22","doi-asserted-by":"crossref","unstructured":"Fischman, S. & Ofran, Y. Computational design of antibodies. Curr. Opin. Struct. Biol. 51, 156\u2013162 (2018).","DOI":"10.1016\/j.sbi.2018.04.007"},{"key":"778_CR23","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/978-1-0716-1450-1_4","volume":"2313","author":"A-M Wolf P\u00e9rez","year":"2022","unstructured":"Wolf P\u00e9rez, A.-M., Lorenzen, N., Vendruscolo, M. & Sormanni, P. Assessment of therapeutic antibody developability by combinations of in vitro and in silico methods. Methods Mol. Biol. 2313, 57\u2013113 (2022).","journal-title":"Methods Mol. Biol."},{"key":"778_CR24","doi-asserted-by":"publisher","unstructured":"Fern\u00e1ndez-Quintero, M. L. et al. Assessing developability early in the discovery process for novel biologics. mAbs https:\/\/doi.org\/10.1080\/19420862.2023.2171248 (2023).","DOI":"10.1080\/19420862.2023.2171248"},{"key":"778_CR25","doi-asserted-by":"publisher","unstructured":"Svilenov, H. L., Arosio, P., Menzen, T., Tessier, P. & Sormanni, P. Approaches to expand the conventional toolbox for discovery and selection of antibodies with drug-like physicochemical properties. mAbs https:\/\/doi.org\/10.1080\/19420862.2022.2164459 (2023).","DOI":"10.1080\/19420862.2022.2164459"},{"key":"778_CR26","first-page":"426","volume":"17","author":"L Gentiluomo","year":"2020","unstructured":"Gentiluomo, L. et al. Advancing therapeutic protein discovery and development through comprehensive computational and biophysical characterization. Mol. Pharm. 17, 426\u2013440 (2020).","journal-title":"Mol. Pharm."},{"key":"778_CR27","doi-asserted-by":"publisher","first-page":"e61393","DOI":"10.7554\/eLife.61393","volume":"9","author":"CT Boughter","year":"2020","unstructured":"Boughter, C. T. et al. Biochemical patterns of antibody polyreactivity revealed through a bioinformatics-based analysis of CDR loops. eLlife 9, e61393 (2020).","journal-title":"eLlife"},{"key":"778_CR28","doi-asserted-by":"publisher","unstructured":"Akbar, R. et al. Progress and challenges for the machine learning-based design of fit-for-purpose monoclonal antibodies. mAbs https:\/\/doi.org\/10.1080\/19420862.2021.2008790 (2022).","DOI":"10.1080\/19420862.2021.2008790"},{"key":"778_CR29","doi-asserted-by":"publisher","unstructured":"Khetan, R. et al. Current advances in biopharmaceutical informatics: guidelines, impact and challenges in the computational developability assessment of antibody therapeutics. mAbs https:\/\/doi.org\/10.1080\/19420862.2021.2020082 (2022).","DOI":"10.1080\/19420862.2021.2020082"},{"key":"778_CR30","doi-asserted-by":"publisher","first-page":"4025","DOI":"10.1073\/pnas.1810576116","volume":"116","author":"MIJ Raybould","year":"2019","unstructured":"Raybould, M. I. J. et al. Five computational developability guidelines for therapeutic antibody profiling. Proc. Natl Acad. Sci. USA 116, 4025\u20134030 (2019).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"778_CR31","doi-asserted-by":"publisher","first-page":"2555","DOI":"10.1021\/acs.molpharmaceut.0c00257","volume":"17","author":"Y Zhang","year":"2020","unstructured":"Zhang, Y. et al. Physicochemical rules for identifying monoclonal antibodies with drug-like specificity. Mol. Pharm. 17, 2555\u20132569 (2020).","journal-title":"Mol. Pharm."},{"key":"778_CR32","first-page":"6307","volume":"2017","author":"A Van Den Oord","year":"2017","unstructured":"Van Den Oord, A., Vinyals, O. & Kavukcuoglu, K. Neural discrete representation learning. Adv. Neural Inf. Process. Syst. 2017, 6307\u20136316 (2017).","journal-title":"Adv. Neural Inf. Process. Syst."},{"key":"778_CR33","doi-asserted-by":"publisher","unstructured":"Lancucki, A. et al. Robust training of vector quantized bottleneck models. In Proc. 2020 International Joint Conference on Neural Networks (IJCNN) 1\u20137 (IEEE, 2020); https:\/\/doi.org\/10.1109\/IJCNN48605.2020.9207145","DOI":"10.1109\/IJCNN48605.2020.9207145"},{"key":"778_CR34","doi-asserted-by":"crossref","unstructured":"Vincent, P., Larochelle, H., Bengio, Y. & Manzagol, P.-A. Extracting and composing robust features with denoising autoencoders. In Proc. 25th International Conference on Machine Learning 1096\u20131103 (Association for Computing Machinery, 2008).","DOI":"10.1145\/1390156.1390294"},{"key":"778_CR35","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1002\/pro.4205","volume":"31","author":"TH Olsen","year":"2022","unstructured":"Olsen, T. H., Boyles, F. & Deane, C. M. Observed Antibody Space: a diverse database of cleaned, annotated, and translated unpaired and paired antibody sequences. Protein Sci. 31, 141\u2013146 (2022).","journal-title":"Protein Sci."},{"key":"778_CR36","doi-asserted-by":"publisher","first-page":"2020203","DOI":"10.1080\/19420862.2021.2020203","volume":"14","author":"D Prihoda","year":"2023","unstructured":"Prihoda, D. et al. BioPhi: a platform for antibody design, humanization and humanness evaluation based on natural antibody repertoires and deep learning. mAbs. 14, 2020203 (2023).","journal-title":"mAbs."},{"key":"778_CR37","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1093\/protein\/gzz031","volume":"32","author":"AM Wollacott","year":"2019","unstructured":"Wollacott, A. M. et al. Quantifying the nativeness of antibody sequences using long short-term memory networks. Protein Eng. Des. Sel. 32, 347\u2013354 (2019).","journal-title":"Protein Eng. Des. Sel."},{"key":"778_CR38","doi-asserted-by":"publisher","first-page":"4041","DOI":"10.1093\/bioinformatics\/btab434","volume":"37","author":"C Marks","year":"2021","unstructured":"Marks, C., Hummer, A. M., Chin, M. & Deane, C. M. Humanization of antibodies using a machine learning approach on large-scale repertoire data. Bioinformatics 37, 4041\u20134047 (2021).","journal-title":"Bioinformatics"},{"key":"778_CR39","doi-asserted-by":"publisher","unstructured":"Vaisman-Mentesh, A., Gutierrez-Gonzalez, M., DeKosky, B. J. & Wine, Y. The molecular mechanisms that underlie the immune biology of anti-drug antibody formation following treatment with monoclonal antibodies. Front. Immunol. https:\/\/doi.org\/10.3389\/fimmu.2020.01951 (2020).","DOI":"10.3389\/fimmu.2020.01951"},{"key":"778_CR40","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.jmb.2005.07.038","volume":"352","author":"D Saerens","year":"2005","unstructured":"Saerens, D. et al. Identification of a universal VHH framework to graft non-canonical antigen-binding loops of camel single-domain antibodies. J. Mol. Biol. 352, 597\u2013607 (2005).","journal-title":"J. Mol. Biol."},{"key":"778_CR41","doi-asserted-by":"publisher","first-page":"3273","DOI":"10.1074\/jbc.M806889200","volume":"284","author":"C Vincke","year":"2009","unstructured":"Vincke, C. et al. General strategy to humanize a camelid single-domain antibody and identification of a universal humanized nanobody scaffold. J. Biol. Chem. 284, 3273\u20133284 (2009).","journal-title":"J. Biol. Chem."},{"key":"778_CR42","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1038\/332323a0","volume":"332","author":"L Riechmann","year":"1988","unstructured":"Riechmann, L., Clark, M., Waldmann, H. & Winter, G. Reshaping human antibodies for therapy. Nature 332, 323\u2013327 (1988).","journal-title":"Nature"},{"key":"778_CR43","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1128\/JCM.40.3.480-489.2002","volume":"40","author":"P Saengjaruk","year":"2002","unstructured":"Saengjaruk, P. et al. Diagnosis of human leptospirosis by monoclonal antibody-based antigen detection in urine. J. Clin. Microbiol. 40, 480\u2013489 (2002).","journal-title":"J. Clin. Microbiol."},{"key":"778_CR44","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.str.2021.11.006","volume":"30","author":"Z Sang","year":"2022","unstructured":"Sang, Z., Xiang, Y., Bahar, I. & Shi, Y. Llamanade: an open-source computational pipeline for robust nanobody humanization. Structure 30, 418\u2013429.e3 (2022).","journal-title":"Structure"},{"key":"778_CR45","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.16228.001","author":"S Moutel","year":"2016","unstructured":"Moutel, S. et al. NaLi-H1: a universal synthetic library of humanized nanobodies providing highly functional antibodies and intrabodies. eLife https:\/\/doi.org\/10.7554\/eLife.16228.001 (2016).","journal-title":"eLife"},{"key":"778_CR46","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1126\/science.abe4747","volume":"370","author":"Y Xiang","year":"2020","unstructured":"Xiang, Y. et al. Versatile and multivalent nanobodies efficiently neutralize SARS-CoV-2. Science 370, 1479\u20131484 (2020).","journal-title":"Science"},{"key":"778_CR47","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/0161-5890(91)90163-E","volume":"28","author":"EA Padlan","year":"1991","unstructured":"Padlan, E. A. A possible procedure for reducing the immunogenicity of antibody variable domains while preserving their ligand-binding properties. Mol. Immunol. 28, 489\u2013498 (1991).","journal-title":"Mol. Immunol."},{"key":"778_CR48","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1073\/pnas.91.3.969","volume":"91","author":"MA Roguska","year":"1994","unstructured":"Roguska, M. A. et al. Humanization of murine monoclonal antibodies through variable domain resurfacing. Proc. Natl Acad. Sci. USA 91, 969\u2013973 (1994).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"778_CR49","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1002\/pro.2321","volume":"22","author":"S Vanderhaegen","year":"2013","unstructured":"Vanderhaegen, S. et al. Structure of an early native-like intermediate of \u03b22-microglobulin amyloidogenesis. Protein Sci. 22, 1349\u20131357 (2013).","journal-title":"Protein Sci."},{"key":"778_CR50","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1038\/s42003-023-04927-7","volume":"6","author":"B Abanades","year":"2023","unstructured":"Abanades, B. et al. ImmuneBuilder: deep-learning models for predicting the structures of immune proteins. Commun. Biol. 6, 575 (2023).","journal-title":"Commun. Biol."},{"key":"778_CR51","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1073\/pnas.1008560108","volume":"108","author":"K Domanska","year":"2011","unstructured":"Domanska, K. et al. Atomic structure of a nanobody-trapped domain-swapped dimer of an amyloidogenic \u03b22-microglobulin variant. Proc. Natl Acad. Sci. USA 108, 1314\u20131319 (2011).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"778_CR52","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1126\/science.abe3255","volume":"370","author":"M Schoof","year":"2020","unstructured":"Schoof, M. et al. An ultrapotent synthetic nanobody neutralizes SARS-CoV-2 by stabilizing inactive Spike. Science 370, 1473\u20131479 (2020).","journal-title":"Science"},{"key":"778_CR53","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1006\/jmbi.2001.4662","volume":"309","author":"A Honegger","year":"2001","unstructured":"Honegger, A. & Pluckthun, A. Yet another numbering scheme for immunoglobulin variable domains: an automatic modeling and analysis tool. J. Mol. Biol. 309, 657\u2013670 (2001).","journal-title":"J. Mol. Biol."},{"key":"778_CR54","doi-asserted-by":"publisher","first-page":"e1008736","DOI":"10.1371\/journal.pcbi.1008736","volume":"17","author":"A Hawkins-Hooker","year":"2021","unstructured":"Hawkins-Hooker, A. et al. Generating functional protein variants with variational autoencoders. PLoS Comput. Biol. 17, e1008736 (2021).","journal-title":"PLoS Comput. Biol."},{"key":"778_CR55","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-32986-y","volume":"8","author":"A Clavero-\u00c1lvarez","year":"2018","unstructured":"Clavero-\u00c1lvarez, A. et al. Humanization of antibodies using a statistical inference approach. Sci. Rep. 8, 14820 (2018).","journal-title":"Sci. Rep."},{"key":"778_CR56","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.toxlet.2019.12.027","volume":"324","author":"J Jiang","year":"2020","unstructured":"Jiang, J. et al. Preclinical safety profile of disitamab vedotin: a novel anti-HER2 antibody conjugated with MMAE. Toxicol. Lett. 324, 30\u201337 (2020).","journal-title":"Toxicol. Lett."},{"key":"778_CR57","doi-asserted-by":"crossref","unstructured":"Deeks, E. D. Disitamab vedotin: first approval. Drugs 81, 1929\u20131935 (2021).","DOI":"10.1007\/s40265-021-01614-x"},{"key":"778_CR58","doi-asserted-by":"publisher","first-page":"13509","DOI":"10.1073\/pnas.1919464117","volume":"117","author":"FA Aprile","year":"2020","unstructured":"Aprile, F. A. et al. Rational design of a conformation-specific antibody for the quantification of A\u03b2 oligomers. Proc. Natl Acad. Sci. USA 117, 13509\u201313518 (2020).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"778_CR59","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.sbi.2021.01.008","volume":"69","author":"BJ Wittmann","year":"2021","unstructured":"Wittmann, B. J., Johnston, K. E., Wu, Z. & Arnold, F. H. Advances in machine learning for directed evolution. Curr. Opin. Struct. Biol. 69, 11\u201318 (2021).","journal-title":"Curr. Opin. Struct. Biol."},{"key":"778_CR60","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/s41592-021-01100-y","volume":"18","author":"S Biswas","year":"2021","unstructured":"Biswas, S., Khimulya, G., Alley, E. C., Esvelt, K. M. & Church, G. M. Low-N protein engineering with data-efficient deep learning. Nat. Methods 18, 389\u2013396 (2021).","journal-title":"Nat. Methods"},{"key":"778_CR61","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1038\/s41587-021-01146-5","volume":"40","author":"C Hsu","year":"2022","unstructured":"Hsu, C., Nisonoff, H., Fannjiang, C. & Listgarten, J. Learning protein fitness models from evolutionary and assay-labeled data. Nat. Biotechnol. 40, 1114\u20131122 (2022).","journal-title":"Nat. Biotechnol."},{"key":"778_CR62","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1038\/s41592-019-0598-1","volume":"16","author":"EC Alley","year":"2019","unstructured":"Alley, E. C., Khimulya, G., Biswas, S., AlQuraishi, M. & Church, G. M. Unified rational protein engineering with sequence-based deep representation learning. Nat. Methods 16, 1315\u20131322 (2019).","journal-title":"Nat. Methods"},{"key":"778_CR63","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-31457-3","volume":"13","author":"EK Makowski","year":"2022","unstructured":"Makowski, E. K. et al. Co-optimization of therapeutic antibody affinity and specificity using machine learning models that generalize to novel mutational space. Nat. Commun. 13, 3788 (2022).","journal-title":"Nat. Commun."},{"key":"778_CR64","doi-asserted-by":"publisher","unstructured":"Tsuruta, H. et al. AVIDa-hIL6: a large-scale VHH dataset produced from an immunized alpaca for predicting antigen-antibody interactions. Preprint at arXiv https:\/\/doi.org\/10.48550\/arXiv.2306.03329 (2023).","DOI":"10.48550\/arXiv.2306.03329"},{"key":"778_CR65","doi-asserted-by":"publisher","first-page":"e0161801","DOI":"10.1371\/journal.pone.0161801","volume":"11","author":"X Li","year":"2016","unstructured":"Li, X. et al. Comparative analysis of immune repertoires between Bactrian camel\u2019s conventional and heavy-chain antibodies. PLoS ONE 11, e0161801 (2016).","journal-title":"PLoS ONE"},{"key":"778_CR66","doi-asserted-by":"publisher","first-page":"e1004552","DOI":"10.1371\/journal.ppat.1004552","volume":"10","author":"LE McCoy","year":"2014","unstructured":"McCoy, L. E. et al. Molecular evolution of broadly neutralizing llama antibodies to the CD4-binding site of HIV-1. PLoS Pathog. 10, e1004552 (2014).","journal-title":"PLoS Pathog."},{"key":"778_CR67","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.cels.2021.01.003","volume":"12","author":"Y Xiang","year":"2021","unstructured":"Xiang, Y. et al. Integrative proteomics identifies thousands of distinct, multi-epitope, and high-affinity nanobodies. Cell Syst. 12, 220\u2013234.e9 (2021).","journal-title":"Cell Syst."},{"key":"778_CR68","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1093\/bioinformatics\/btv552","volume":"32","author":"J Dunbar","year":"2016","unstructured":"Dunbar, J. & Deane, C. M. ANARCI: antigen receptor numbering and receptor classification. Bioinformatics 32, 298\u2013300 (2016).","journal-title":"Bioinformatics"},{"key":"778_CR69","doi-asserted-by":"publisher","unstructured":"Zeghidour, N., Luebs, A., Omran, A., Skoglund, J. & Tagliasacchi, M. SoundStream: an end-to-end neural audio codec. Preprint at arXiv https:\/\/doi.org\/10.48550\/arXiv.2107.03312 (2021).","DOI":"10.48550\/arXiv.2107.03312"},{"key":"778_CR70","doi-asserted-by":"publisher","unstructured":"Yu, J. et al. Vector-quantized image modeling with improved VQGAN. Preprint at arXiv https:\/\/doi.org\/10.48550\/arXiv.2110.04627 (2022).","DOI":"10.48550\/arXiv.2110.04627"},{"key":"778_CR71","first-page":"2390","volume":"80","author":"\u0141 Kaiser","year":"2018","unstructured":"Kaiser, \u0141. et al. Fast decoding in sequence models using discrete latent variables. Proc. Mach. Learn. Res. 80, 2390\u20132399 (2018).","journal-title":"Proc. Mach. Learn. Res."},{"key":"778_CR72","unstructured":"Devlin, J., Chang, M.-W., Lee, K. & Toutanova, K. BERT: pre-training of deep bidirectional transformers for language understanding. In Proc. 2019 Conference of the North American Chapter of the Association for Computational Linguistics (eds Burstein, J. et al.) 4171\u20134186 (ACL, 2019)."},{"key":"778_CR73","unstructured":"Paszke, A. et al. PyTorch: an imperative style, high-performance deep learning library. In Proc. Annual Conference on Neural Information Processing Systems 2019 (eds Wallach, H et al.) 8024\u20138037 (Curran Associates, 2019)."},{"key":"778_CR74","unstructured":"Kingma, D. P. & Ba, J. Adam: a method for stochastic optimization. In Proc. 3rd International Conference on Learning Representations (ICLR, 2015)."},{"key":"778_CR75","doi-asserted-by":"publisher","unstructured":"Lefranc, M. P. & Lefranc, G. Immunoglobulins or antibodies: IMGT\u00ae bridging genes, structures and functions. Biomedicines https:\/\/doi.org\/10.3390\/biomedicines8090319 (2020).","DOI":"10.3390\/biomedicines8090319"},{"key":"778_CR76","doi-asserted-by":"publisher","first-page":"1758291","DOI":"10.1080\/19420862.2020.1758291","volume":"12","author":"S Schmitz","year":"2020","unstructured":"Schmitz, S., Soto, C., Crowe, J. E. Jr & Meiler, J. Human-likeness of antibody biologics determined by back-translation and comparison with large antibody variable gene repertoires. mAbs 12, 1758291 (2020).","journal-title":"mAbs"},{"key":"778_CR77","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/1472-6750-13-55","volume":"13","author":"SH Gao","year":"2013","unstructured":"Gao, S. H., Huang, K., Tu, H. & Adler, A. S. Monoclonal antibody humanness score and its applications. BMC Biotechnol. 13, 55 (2013).","journal-title":"BMC Biotechnol."},{"key":"778_CR78","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1016\/j.jmb.2007.02.100","volume":"369","author":"KR Abhinandan","year":"2007","unstructured":"Abhinandan, K. R. & Martin, A. C. R. Analyzing the \u2018degree of humanness\u2019 of antibody sequences. J. Mol. Biol. 369, 852\u2013862 (2007).","journal-title":"J. Mol. Biol."},{"key":"778_CR79","doi-asserted-by":"publisher","first-page":"D383","DOI":"10.1093\/nar\/gkz827","volume":"48","author":"MIJ Raybould","year":"2020","unstructured":"Raybould, M. I. J. et al. Thera-SAbDab: the therapeutic structural antibody database. Nucleic Acids Res. 48, D383\u2013D388 (2020).","journal-title":"Nucleic Acids Res."},{"key":"778_CR80","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/0022-2836(73)90011-9","volume":"79","author":"A Shrake","year":"1973","unstructured":"Shrake, A. & Rupley, J. A. Environment and exposure to solvent of protein atoms. Lysozyme and insulin. J. Mol. Biol. 79, 351\u2013371 (1973).","journal-title":"J. Mol. Biol."},{"key":"778_CR81","doi-asserted-by":"publisher","first-page":"80635","DOI":"10.1371\/journal.pone.0080635","volume":"8","author":"MZ Tien","year":"2013","unstructured":"Tien, M. Z., Meyer, A. G., Sydykova, D. K., Spielman, S. J. & Wilke, C. O. Maximum allowed solvent accessibilities of residues in proteins. PLoS ONE 8, 80635 (2013).","journal-title":"PLoS ONE"},{"key":"778_CR82","doi-asserted-by":"publisher","first-page":"3193","DOI":"10.1093\/nar\/gki633","volume":"33","author":"H Chen","year":"2005","unstructured":"Chen, H. & Zhou, H.-X. Prediction of solvent accessibility and sites of deleterious mutations from protein sequence. Nucleic Acids Res. 33, 3193\u20133199 (2005).","journal-title":"Nucleic Acids Res."},{"key":"778_CR83","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1110\/ps.9.5.831","volume":"9","author":"L Esposito","year":"2000","unstructured":"Esposito, L., Vitagliano, L., Zagari, A. & Mazzarella, L. Pyramidalization of backbone carbonyl carbon atoms in proteins. Protein Sci. 9, 2038\u20132042 (2000).","journal-title":"Protein Sci."},{"key":"778_CR84","doi-asserted-by":"publisher","unstructured":"Ramon, A. et al. AbNatiV 1.0. Zenodo https:\/\/doi.org\/10.5281\/zenodo.10171047 (2023).","DOI":"10.5281\/zenodo.10171047"}],"container-title":["Nature Machine Intelligence"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s42256-023-00778-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42256-023-00778-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42256-023-00778-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,24]],"date-time":"2024-01-24T00:04:18Z","timestamp":1706054658000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s42256-023-00778-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,15]]},"references-count":84,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,1]]}},"alternative-id":["778"],"URL":"https:\/\/doi.org\/10.1038\/s42256-023-00778-3","relation":{},"ISSN":["2522-5839"],"issn-type":[{"value":"2522-5839","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,15]]},"assertion":[{"value":"30 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}